Skip to main content

Table 2 Results from the multivariable logistic regression model for EGFR testing

From: Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma

 

OR (95% CI)

p-value

Month of diagnosis, 1-month increase

1.19 (1.08–1.31)

 < 0.001

Age at diagnosis, 5-year increase

1.02 (0.95–1.09)

0.59

Sex

 Female

1.06 (0.89–1.27)

0.49

 Male (ref)

1

 

Race

 White (ref)

1

 

 Black

0.76 (0.55–1.06)

0.11

 Asian

1.15 (0.79–1.68)

0.47

 Other (including unknown)

0.81 (0.55–1.20)

0.29

Ethnicity

 Non-Hispanic (ref)

1

 

 Hispanic

0.93 (0.62–1.37)

0.70

Marital status

 Not married/unknown (ref)

1

 

 Married

1.15 (0.97–1.38)

0.12

Urban/rural code

 Big metro (ref)

1

 

 Metro

0.93 (0.77–1.13)

0.47

 Urban

0.79 (0.55–1.14)

0.21

 Less urban/rural

0.67 (0.50–0.91)

0.010

Census tract poverty indicator

 0 to < 5% (ref)

1

 

 5% to < 10%

1.07 (0.85–1.34)

0.57

 10% to < 20%

0.96 (0.76–1.20)

0.70

 20% to 100%

0.90 (0.69–1.18)

0.44

Medicaid dual-eligibility

 Yes

0.81 (0.64–1.02)

0.07

 No (ref)

1

 

Charlson score

 0 (ref)

1

 

 1

0.87 (0.70–1.07)

0.18

 2

0.92 (0.71–1.20)

0.55

 ≥ 3

0.70 (0.56–0.89)

0.003

Radiation

 Yes

0.99 (0.84–1.18)

0.95

 No (ref)

1

Â